AR054778A1 - Uso de sangliferina en hcv - Google Patents
Uso de sangliferina en hcvInfo
- Publication number
- AR054778A1 AR054778A1 ARP060102543A ARP060102543A AR054778A1 AR 054778 A1 AR054778 A1 AR 054778A1 AR P060102543 A ARP060102543 A AR P060102543A AR P060102543 A ARP060102543 A AR P060102543A AR 054778 A1 AR054778 A1 AR 054778A1
- Authority
- AR
- Argentina
- Prior art keywords
- acid residue
- alpha
- macrocyclic ring
- formula
- alkyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Uso de un compuesto macrolido tal como una sangliferina para el tratamiento y prevencion de la hepatitis C y enfermedades relacionadas tales como fibrosis hepática, cirrosis hepática y carcinoma hepatocelular carcinoma. Reivindicacion 2: Un método de acuerdo con la reivindicacion 1 en el cual el macrolido es una sangliferina de formula (7) S--L-M donde S representa un alquilo C1-10 de cadena recta o ramificada; L representa un ligante que comprende una secuencia lineal de entre 6 y 11 átomos de C; y M representa un anillo macrocíclico donde las posiciones 2 a 6 de dicho anillo macrocíclico son proporcionadas mediante un residuo ácido piperidazinil-carboxílico sustituido o no sustituido de formula (1); donde las posiciones 7 a 9 de dicho anillo macrocíclico son proporcionadas mediante un residuo alfa-aminoácido aromático donde la porcion carboxi del residuo alfa-aminoácido ocupa la posicion 7 de dicho anillo macrocíclico, y la porcion alfa-amino del residuo alfa-aminoácido aromático ocupa la posicion 9 de dicho anillo macrocíclico, las posiciones 10 a 12 de dicho anillo macrocíclico son proporcionadas mediante un residuo alfa-aminoácido alifático donde la posicion carboxi del residuo alfa-aminoácido alifático ocupa la posicion 10 de dicho anillo macrocíclico y la posicion alfa-amino del residuo a-aminoácido alifático ocupa la posicion 12 de dicho anillo macrocíclico, comprendiendo el resto del anillo macrocíclico un residuo ácido hidrocarboxílico que tiene una longitud de cadena de 6 a 20 átomos de C, cuya porcion oxi completa un ligamento de lactona macrocíclico y cuya porcion carbonilo forma un ligamiento amida con el grupo alfa-amino en la posicion 12 del anillo macrocíclico, en forma libre o protegida, o su sal. Reivindicacion 9: Una combinacion farmacéutica que compende a) un primer agente el cual es un compuesto de union a ciclofilina tal como una sangliferina, y b) un co-agente que tiene propiedades anti-VHC. Reivindicacion 11: Un método, uso, composicion o combinacion de acuerdo con cualquiera de las reivindicaciones precedentes, donde el compuesto de union a ciclofilina es un compuesto de la formula (1) donde X es H, metoxi, etoxi, OnPr, OiPr; R14 y R15 son independientemente H, metilo, alquilo, alquilo C1-4, C1-4-CO-CH3, o R14 y R15 se fusionan para formar un cicloalquilo sustituido o no sustituido de 5 a 76 miembros: seleccionado de la formula (2) R16 es H, o Me o alquilo C1-4; R17 es H, OH, -O-alquilo C1-4 o R14, R15 y R17 se fusionan para formar un cicloalquilo de la formula (3); R23 es H, alquilo C1-10 de cadena recta o ramificada y/o que contiene uno o más ligamientos insaturados en articular enlaces dobles o triples acumulativos a lo largo de su longitud. Reivindicacion 12: Un método, uso, composicion o combinacion de acuerdo con la reivindicacion 11 donde R23 se selecciona del grupo formado por -CH=CH2., -CH2-OH, -CH2-OCH3, -CHO, -COOH, o de formula (19).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US69149705P | 2005-06-17 | 2005-06-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR054778A1 true AR054778A1 (es) | 2007-07-18 |
Family
ID=37075234
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060102543A AR054778A1 (es) | 2005-06-17 | 2006-06-15 | Uso de sangliferina en hcv |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20090221598A1 (es) |
| EP (1) | EP1893211B1 (es) |
| JP (1) | JP2008546708A (es) |
| KR (1) | KR20080033274A (es) |
| CN (1) | CN101242842A (es) |
| AR (1) | AR054778A1 (es) |
| AT (1) | ATE524183T1 (es) |
| AU (1) | AU2006259348B2 (es) |
| BR (1) | BRPI0613142A2 (es) |
| CA (1) | CA2611151A1 (es) |
| EC (1) | ECSP078029A (es) |
| GT (1) | GT200600262A (es) |
| MA (1) | MA29600B1 (es) |
| MX (1) | MX2007016068A (es) |
| NO (1) | NO20080351L (es) |
| PE (1) | PE20070118A1 (es) |
| RU (1) | RU2427372C2 (es) |
| TN (1) | TNSN07477A1 (es) |
| TW (1) | TW200740438A (es) |
| WO (1) | WO2006138507A1 (es) |
| ZA (1) | ZA200710551B (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102224242B (zh) * | 2008-09-24 | 2014-09-24 | 中国科学院上海有机化学研究所 | 新基因簇 |
| WO2011011632A1 (en) * | 2009-07-22 | 2011-01-27 | Tufts University | Methods and compositions for modulating membrane potential to influence cell behavior |
| US20110117055A1 (en) | 2009-11-19 | 2011-05-19 | Macdonald James E | Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds |
| EP2533784B1 (en) | 2010-02-09 | 2015-04-22 | Neurovive Pharmaceutical AB | Sanglifehrin based compounds |
| WO2011098805A1 (en) | 2010-02-09 | 2011-08-18 | Biotica Technology Limited | Sanglifehrin based compounds |
| WO2011098808A1 (en) | 2010-02-09 | 2011-08-18 | Biotica Technology Limited | Sanglifehrin based compounds |
| GB201008123D0 (en) | 2010-05-17 | 2010-06-30 | Biotica Tech Ltd | Novel compounds |
| UY33775A (es) * | 2010-12-10 | 2012-07-31 | Gilead Sciences Inc | Inhibidores macrocíclicos de virus flaviviridae, composiciones farmacéuticas que los comprenden y sus usos |
| EP3427737A1 (en) | 2010-12-20 | 2019-01-16 | NeuroVive Pharmaceutical AB | Sanglifehrin derivatives and methods for their production |
| JO3063B1 (ar) | 2011-03-29 | 2017-03-15 | Neurovive Pharmaceutical Ab | مركب مبتكر وطرق لانتاجه |
| WO2012145427A1 (en) * | 2011-04-18 | 2012-10-26 | The Trustees Of Columbia University In The City Of New York | Methods to treat cancer using cyclosporine and cyclosporine derivatives |
| GB201118334D0 (en) | 2011-10-24 | 2011-12-07 | Biotica Tech Ltd | Novel dosage form |
| AR091279A1 (es) * | 2012-06-08 | 2015-01-21 | Gilead Sciences Inc | Inhibidores macrociclicos de virus flaviviridae |
| JP6209601B2 (ja) * | 2012-06-08 | 2017-10-04 | ギリアード サイエンシーズ， インコーポレイテッド | フラビウイルス科ウイルスの大環状阻害剤 |
| SI2859009T1 (sl) | 2012-06-08 | 2017-12-29 | Gilead Sciences, Inc. | Makrociklični inhibitorji flaviviridae virusov |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4917888A (en) | 1985-06-26 | 1990-04-17 | Cetus Corporation | Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| JP2514950B2 (ja) | 1986-03-10 | 1996-07-10 | エフ・ホフマン―ラ ロシユ アーゲー | 化学修飾蛋白質，その製造法および中間体 |
| GB2222770B (en) | 1988-09-16 | 1992-07-29 | Sandoz Ltd | Pharmaceutical compositions containing cyclosporins |
| DE69132332T2 (de) | 1990-04-06 | 2000-11-30 | Genelabs Tech Inc | Hepatitis c-virus-epitope |
| US5595732A (en) | 1991-03-25 | 1997-01-21 | Hoffmann-La Roche Inc. | Polyethylene-protein conjugates |
| US5382657A (en) | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
| GB9318612D0 (en) | 1993-09-08 | 1993-10-27 | Sandoz Ltd | An assay |
| NZ276943A (en) | 1993-11-10 | 1998-02-26 | Schering Corp Substituted For | Alpha-interferon conjugated to a non-antigenic polymer (preferably a polyalkylene oxide) and its preparation |
| US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| US6124453A (en) | 1995-07-04 | 2000-09-26 | Novartis Ag | Macrolides |
| AR006514A1 (es) | 1995-07-04 | 1999-09-08 | Sandoz Ag | Un macrolido, sus usos, un proceso para producirlo, un aislado biologicamente puro capaz de producirlo, y una composicion farmaceutica quelo comprende |
| US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| US5990276A (en) | 1996-05-10 | 1999-11-23 | Schering Corporation | Synthetic inhibitors of hepatitis C virus NS3 protease |
| NZ335276A (en) | 1996-10-18 | 2000-09-29 | Vertex Pharma | Inhibitors of serine proteases, particularly hepatitis C virus (HCV) NS3 (Non Structural Protein 3) protease |
| GB9623908D0 (en) | 1996-11-18 | 1997-01-08 | Hoffmann La Roche | Amino acid derivatives |
| US6004933A (en) | 1997-04-25 | 1999-12-21 | Cortech Inc. | Cysteine protease inhibitors |
| ES2234144T3 (es) | 1997-08-11 | 2005-06-16 | Boehringer Ingelheim (Canada) Ltd. | Analogos de peptidos inhibidores de la hepatitis c. |
| GB9806815D0 (en) | 1998-03-30 | 1998-05-27 | Hoffmann La Roche | Amino acid derivatives |
| GB9811854D0 (en) * | 1998-06-02 | 1998-07-29 | Ciba Geigy Ag | Organic compounds |
| US6444652B1 (en) | 1998-08-10 | 2002-09-03 | Novirio Pharmaceuticals Limited | β-L-2'-deoxy-nucleosides for the treatment of hepatitis B |
| US6323180B1 (en) | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
| MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
| YU92202A (sh) | 2000-05-26 | 2006-01-16 | Idenix (Cayman) Limited | Metode i smeše za lečenje flavi virusa i pesti virusa |
| ES2227203T3 (es) | 2000-05-26 | 2005-04-01 | Idenix (Cayman) Limited | Metodos para tratar la infeccion por el virus de la hepatitis delta con beta-1-2'-desoxinucleosidos. |
| MY141594A (en) | 2000-06-15 | 2010-05-14 | Novirio Pharmaceuticals Ltd | 3'-PRODRUGS OF 2'-DEOXY-ß-L-NUCLEOSIDES |
| WO2002008251A2 (en) | 2000-07-21 | 2002-01-31 | Corvas International, Inc. | Peptides as ns3-serine protease inhibitors of hepatitis c virus |
| AR029851A1 (es) | 2000-07-21 | 2003-07-16 | Dendreon Corp | Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c |
| HUP0303358A3 (en) | 2000-07-21 | 2005-10-28 | Schering Corp | Novel peptides as ns3-serine protease inhibitors of hepatitis c virus and pharmaceutical compositions containing them |
| AU2001255070A1 (en) | 2000-08-28 | 2002-03-13 | Jin-Sub Kim | Generator of two-wheeled vehicle and lighting system thereby |
| ES2263687T3 (es) | 2000-11-20 | 2006-12-16 | Bristol-Myers Squibb Company | Inhibidores tripeptidicos de la hepatitis c. |
| EP1343807B1 (en) | 2000-12-12 | 2009-04-29 | Schering Corporation | Diaryl peptides as ns3-serine protease inhibitors of hepatits c virus |
| AU2002230764A1 (en) | 2000-12-13 | 2002-06-24 | Bristol-Myers Squibb Pharma Company | Imidazolidinones and their related derivatives as hepatitis c virus ns3 protease inhibitors |
| WO2002048116A2 (en) | 2000-12-13 | 2002-06-20 | Bristol-Myers Squibb Pharma Company | Inhibitors of hepatitis c virus ns3 protease |
| AU2003248748A1 (en) | 2002-06-28 | 2004-01-19 | Idenix (Cayman) Limited | 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
| GB0320638D0 (en) | 2003-09-03 | 2003-10-01 | Novartis Ag | Organic compounds |
| JP4892486B2 (ja) * | 2004-10-01 | 2012-03-07 | デビオファーム ソシエテ アノニム | Ｃ型肝炎感染の治療のための［ｄ−ｍｅａｌａ］３−［ｅｔｖａｌ］４−シクロスポリンの使用、及び当該［ｄ−ｍｅａｌａ］３−［ｅｔｖａｌ］４−シクロスポリンを含む医薬組成物 |
| US7897565B2 (en) * | 2004-12-23 | 2011-03-01 | Novartis Ag | Compositions for HCV treatment |
-
2006
- 2006-06-15 EP EP06784962A patent/EP1893211B1/en not_active Not-in-force
- 2006-06-15 JP JP2008517117A patent/JP2008546708A/ja active Pending
- 2006-06-15 CN CNA2006800297685A patent/CN101242842A/zh active Pending
- 2006-06-15 AR ARP060102543A patent/AR054778A1/es unknown
- 2006-06-15 BR BRPI0613142-5A patent/BRPI0613142A2/pt not_active IP Right Cessation
- 2006-06-15 RU RU2008100587/15A patent/RU2427372C2/ru not_active IP Right Cessation
- 2006-06-15 US US11/917,781 patent/US20090221598A1/en not_active Abandoned
- 2006-06-15 AT AT06784962T patent/ATE524183T1/de not_active IP Right Cessation
- 2006-06-15 KR KR1020087001271A patent/KR20080033274A/ko not_active Application Discontinuation
- 2006-06-15 MX MX2007016068A patent/MX2007016068A/es not_active Application Discontinuation
- 2006-06-15 WO PCT/US2006/023394 patent/WO2006138507A1/en active Application Filing
- 2006-06-15 CA CA002611151A patent/CA2611151A1/en not_active Abandoned
- 2006-06-15 AU AU2006259348A patent/AU2006259348B2/en not_active Ceased
- 2006-06-16 GT GT200600262A patent/GT200600262A/es unknown
- 2006-06-16 TW TW095121787A patent/TW200740438A/zh unknown
- 2006-06-16 PE PE2006000682A patent/PE20070118A1/es not_active Application Discontinuation
-
2007
- 2007-12-04 ZA ZA200710551A patent/ZA200710551B/xx unknown
- 2007-12-14 TN TNP2007000477A patent/TNSN07477A1/en unknown
- 2007-12-17 EC EC2007008029A patent/ECSP078029A/es unknown
- 2007-12-26 MA MA30507A patent/MA29600B1/fr unknown
-
2008
- 2008-01-16 NO NO20080351A patent/NO20080351L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| MA29600B1 (fr) | 2008-07-01 |
| AU2006259348A1 (en) | 2006-12-28 |
| KR20080033274A (ko) | 2008-04-16 |
| RU2427372C2 (ru) | 2011-08-27 |
| EP1893211A1 (en) | 2008-03-05 |
| GT200600262A (es) | 2007-03-28 |
| US20090221598A1 (en) | 2009-09-03 |
| ECSP078029A (es) | 2008-01-23 |
| CA2611151A1 (en) | 2006-12-28 |
| EP1893211B1 (en) | 2011-09-14 |
| NO20080351L (no) | 2008-03-14 |
| ATE524183T1 (de) | 2011-09-15 |
| PE20070118A1 (es) | 2007-02-23 |
| BRPI0613142A2 (pt) | 2010-12-21 |
| RU2008100587A (ru) | 2009-07-27 |
| ZA200710551B (en) | 2008-11-26 |
| WO2006138507A1 (en) | 2006-12-28 |
| TNSN07477A1 (en) | 2009-03-17 |
| AU2006259348B2 (en) | 2010-07-22 |
| TW200740438A (en) | 2007-11-01 |
| JP2008546708A (ja) | 2008-12-25 |
| MX2007016068A (es) | 2008-03-10 |
| CN101242842A (zh) | 2008-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR054778A1 (es) | Uso de sangliferina en hcv | |
| AR047793A1 (es) | Inhibidores de la serina proteasa ns-3 del vhc | |
| AR083070A1 (es) | Analogos de nucleotidos sustituidos con heterociclos nitrogenados, composiciones farmaceuticas que los contienen y uso de los mismos para tratar enfermedades virales, en particular infecciones por vhc | |
| PE20070210A1 (es) | Compuestos macrociclicos como inhibidores del virus de hepatitis c | |
| AR030591A1 (es) | Inhibidores de proteasa peptidomimetica | |
| AR023260A1 (es) | Peptidos macrociclicos activos frente al virus de la hepatitis c. | |
| EA200970478A1 (ru) | Аналоги тиофена для лечения или предупреждения флавивирусных инфекций | |
| AR056327A1 (es) | Compuestos de nucleosidos para el tratamiento de infecciones virales | |
| RU2015148010A (ru) | Высокоактивное производное нуклеозида для лечения hcv | |
| HK1083337A1 (en) | Quinoxalinyl macrocyclic hepatitis c serine protease inhibitors | |
| JP2012504632A5 (es) | ||
| WO2008002924A3 (en) | Quinoxalinyl macrocyclic hepatitis c virus serine protease inhibitors | |
| PE20110212A1 (es) | (1aR, 5S, 8S, 10R, 22aR)-5-TERT-BUTIL-N-{(1R, 2S)-1-{[(CICLOPROPILSULFONIL) AMINO] CARBONIL}-2-VINILCICLOPROPIL}-14-METOXI-3,6-DIOXO-1, 1a, 3, 4, 5, 6, 9, 10, 18, 19, 20, 21, 22, 22a-TETRADECAHIDRO-8H-7, 10-METANOCICLOPROPA[18, 19] [1, 10, 3, 6] DIOXADIAZACICLONONADECINO[11, 12-b] QUINOXALIN-8-CARBOXAMIDA COMO INHIBIDOR DE LA PROTEASA HCV NS3 | |
| PE20070343A1 (es) | Inhibidores macrociclicos del virus de la hepatitis c | |
| KR950704330A (ko) | 면역억제제로서의 라파마이신 카보네이트 에스테르(Rapamycin carbonate esters as immunosuppressant agents) | |
| RS20110578A2 (en) | MACROCYCLIC CARBOXYLIC ACIDS AND ACYLSULPHONAMIDES AS HCV REPLICATION INHIBITORS | |
| BRPI0519345A2 (pt) | composiÇço para tratamento do hcv | |
| ECSP077402A (es) | Derivados de 2-amido-4-feniltiazol, su preparación y su aplicación en terapéutica | |
| PE20080144A1 (es) | Compuestos de tetrahidropiridotienopirimidina con actividad antiproliferativa | |
| JP2012510438A5 (es) | ||
| PE20060602A1 (es) | Derivados de heteroaril acil pirrolidina como inhibidores del virus de la hepatitis c (hcv) | |
| AR113826A1 (es) | Indol-2-carboxamidas sustituidas con amino-tiazol activas contra el virus de la hepatitis b (vhb) | |
| AR059619A1 (es) | Derivados halogenados de sulfonamidas | |
| AR094122A1 (es) | Compuestos triciclicos moduladores de la actividad de cftr | |
| PE20141391A1 (es) | Combinacion que comprende un compuesto con actividad antiviral y un agente terapeutico |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |